Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | CCR6 | P51684 | 2/20 | 0.54 |
| ▸ | G6PD | P11413 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 7/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198527 | 1.00 | PKM (0.58) | PKMALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL30435094 | 0.82 | MGLL (0.59) | PKMALDH1A1HPGDMAPTHSP90AA1 | |
| SCHEMBL1164427 | 0.82 | MGLL (0.59) | PKMALDH1A1HPGDMAPTHSP90AA1 | |
| SCHEMBL2345040 | 0.82 | MAPT (0.61) | PKMALDH1A1HPGDMAPTHSP90AA1 | |
| SCHEMBL9876149 | 0.81 | MAPT (0.60) | PKMALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL11611638 | 0.81 | MAPT (0.64) | PKMALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL10587456 | 0.78 | MGLL (0.57) | PKMALDH1A1HPGDMAPTHSP90AA1 | |
| SCHEMBL94095 | 0.78 | MGLL (0.57) | PKMHSP90AA1NPSR1CCR6G6PD | |
| SCHEMBL25580607 | 0.78 | CCR6 (0.59) | PKMALDH1A1HPGDMAPTHSP90AA1 | |
| SCHEMBL15758697 | 0.77 | MGLL (0.59) | ALDH1A1HPGDMAPTHSP90AA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525864-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MANAGING SICKLE CELL DISEASE AND CONDITIONS RELATED THERETO | Emory University (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2023225300-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MANAGING SICKLE CELL DISEASE AND CONDITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2023-11-23 | — | — | WO | claimed |
| CN-115591418-B | Diaphragm for trapping dioxin and preparation method thereof | 佛山(华南)新材料研究院 | 2023-06-09 | — | — | CN | claimed |
| CN-115591418-A | Membrane for trapping dioxin and preparation method thereof | 佛山（华南）新材料研究院（CN） | 2023-01-13 | — | — | CN | claimed |
| EP-4061961-B1 | METHOD FOR DOUBLE STRAND SEQUENCING | OXFORD NANOPORE TECH PLC (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260072009-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20260072008-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | UNIV OXFORD INNOVATION LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20260063618-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | Oxford Nanopore Technolgies PLC (GB) | 2026-03-05 | — | — | US | disclosed |
| EP-4270008-B1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | OXFORD NANOPORE TECH PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| EP-4127711-B1 | METHOD OF DETECTING AN ANALYTE IN A MEDIUM COMPRISING A LIGHT SCATTERING CONSTITUENT | KING S COLLEGE LONDON (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4662489-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | Oxford University Innovation Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-20250361243-A1 | Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto | UNIV EMORY (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2021111139-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021099801-A1 | METHOD FOR DOUBLE STRAND SEQUENCING | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2021-05-27 | — | — | WO | disclosed |
| CN-112189054-A | Method of producing a composite material | 牛津纳米孔科技公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20130025495-A1 | COMPOSITIONS COMPRISING A REACTIVE MONOMER AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130025495-A1 | COMPOSITIONS COMPRISING A REACTIVE MONOMER AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130025495-A1 | COMPOSITIONS COMPRISING A REACTIVE MONOMER AND USES THEREOF | ISP INVESTMENTS INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-6153645-A | FOR INHIBITING GROWTH OF MICROORGANISMS; INHIBITOR OF AMINOACYL-TRNA SYNTHETASE | CUBIST PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000017206-A1 | TETRACYCLIC HETEROCYCLES AS ANTIMICROBIAL AGENTS | CUBIST PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072008-A1 | METHOD OF CHARACTERISING A PEPTIDE, POLYPEPTIDE OR PROTEIN USING A NANOPORE | MAX, NPPA, NUP210 | PKM 2308/4885ALDH1A1 4882/4885HPGD 4643/4885 |
| US-20130025495-A1 | COMPOSITIONS COMPRISING A REACTIVE MONOMER AND USES THEREOF | MEP1A, MACF1, CYP1B1 | PKM 1982/4885ALDH1A1 34/4885HPGD 694/4885 |
| US-20260063618-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | NUP210, NPPA, NUP160 | PKM 2622/4885ALDH1A1 4884/4885HPGD 4738/4885 |
| US-20250361243-A1 | Compounds and Pharmaceutical Compositions Useful for Managing Sickle Cell Disease and Conditions Related Thereto | THPO, HBG1, HBG2 | PKM 210/4885ALDH1A1 84/4885HPGD 456/4885 |
| US-20260072009-A1 | METHOD OF CHARACTERISING A TARGET POLYPEPTIDE USING A NANOPORE | NUP210, SLC9A2, SLC9A3 | PKM 3231/4885ALDH1A1 4883/4885HPGD 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.